文献速递脊柱关节炎

中轴型脊柱关节炎随机临床试验中疗效与安全性的性别差异:系统文献综述与荟萃分析

Sex-Related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta-Analysis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-03-19

该系统综述与荟萃分析纳入79项随机对照试验(n=23,748例,男性69.7%),评估中轴型脊柱关节炎先进治疗在男女患者间的基线特征、疗效与安全性差异。男性患者在所有先进治疗中达到ASAS40反应(OR 1.88,95%CI 1.44-2.46)和ASDAS-LDA/ID(OR 2.19,95%CI 1.47-3.26)的可能性均高于女性。作者认为未来研究应探讨这些差异背后的生物学(性别相关)和社会文化(社会性别相关)机制。

要点

  • 仅9项试验(11.4%)按性别报告基线特征,22项(28%)报告疗效终点,9项(11.4%)报告安全性终点。
  • 男性在所有先进治疗中达到ASAS40反应的OR为1.88(95%CI 1.44-2.46),高于女性。
  • 男性在所有先进治疗中达到ASDAS-LDA/ID的OR为2.19(95%CI 1.47-3.26),高于女性。

核心结论

  • 女性中轴型脊柱关节炎患者接受先进治疗后达到疗效结局的可能性低于男性,各药物类别间差异相似。
  • 作者认为未来研究应探讨这些差异背后的生物学(性别相关)和社会文化(社会性别相关)机制。

研究设计与样本

  • 系统文献检索截至2023年3月19日评估中轴型脊柱关节炎先进治疗疗效的随机对照试验。
  • 共纳入79项随机对照试验,n=23,748例患者,男性占69.7%。
  • 按性别提取基线特征、ASAS 20/40标准和ASDAS-LDA/ID等结局,采用随机效应模型计算男女应答的合并效应。

主要发现

  • 仅9项试验(11.4%)按性别报告基线特征,22项(28%)报告疗效终点,9项(11.4%)报告安全性终点。
  • 基线时女性年龄显著更大且疼痛评分更高,而男性C反应蛋白水平更高。
  • 所有先进治疗中男性达到ASAS40反应的OR为1.88(95%CI 1.44-2.46),高于女性;IL-17A抑制剂OR为1.82,TNF抑制剂OR为2.42,IL-17A/F抑制剂数值上更高。
  • 所有先进治疗中男性达到ASDAS-LDA/ID的OR为2.19(95%CI 1.47-3.26),高于女性;IL-17A抑制剂OR为2.08,TNF抑制剂OR为2.42。

局限性

  • 仅9项试验(11.4%)按性别报告基线特征,22项(28%)报告疗效终点,9项(11.4%)报告安全性终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to assess differences in baseline characteristics, efficacy, and safety of advanced therapies between male and female patients with axial spondyloarthritis (axSpA) in randomized controlled trials (RCTs). METHODS: We conducted a systematic literature search for RCTs assessing the efficacy of advanced therapies in patients with axSpA until March 19, 2023. We extracted the following outcomes by sex: baseline participant characteristics, Assessment in Spondylarthritis International Society (ASAS) 20/40 criteria, and Axial Spondyloarthritis Disease Activity Score low disease activity or inactive disease (ASDAS-LDA/ID). Random-effects models were used to calculate pooled effects for responses in men versus women for different medication classes. RESULTS: We included 79 RCTs (n = 23,748 patients, 69.7% male). Only 9 trials (11.4%), 22 trials (28%), and 9 trials (11.4%) reported baseline characteristics, efficacy end points, and safety end points by sex, respectively. At baseline, women were significantly older and had higher pain scores, whereas men had higher C-reactive protein levels. Overall, male patients were more likely to achieve an ASAS40 response compared to female patients for all advanced therapies (odds ratio [OR] 1.88, 95% confidence interval [CI] 1.44-2.46) and for interleukin-17A (IL-17A) inhibitors (IL-17Ai) (OR 1.82) and tumor necrosis factor inhibitor (TNFi) (OR 2.42), and male patients had numerically higher values for IL-17A/Fi. Male patients were also more likely to achieve an ASDAS-LDA/ID (OR 2.19, 95% CI 1.47-3.26) across all advanced therapies and for IL-17Ai (OR 2.08) and TNFi (OR 2.42) individually. CONCLUSION: Female patients with axSpA are less likely to achieve efficacy outcomes on advanced therapies compared to their male counterparts, with similar differences across medication classes. Future studies should study the biologic (sex-related) and sociocultural (gender-related) mechanisms underlying these differences.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Gao A, Pardo Pardo J, Dang S, et al. Sex-Related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2025. PMID: 39989255. doi:10.1002/acr.25512

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。